Pharmaceutical System Strengthening : Bangladesh Perspective Aktari Mamtaz Joint Secretary Ministry of Health and Family welfare (MOHFW), Bangladesh.

Slides:



Advertisements
Similar presentations
JFDA & HAI Workshop Towards equitable and affordable medicine prices policy in Jordan 4-5 December 2007 Strategies to aid market entry and competition.
Advertisements

World Health Organization
BACKGROUND: The Directorate General of Drug Administration under the Ministry of Health & Family Welfare, Government of the People's Republic of Bangladesh,
WELCOME HEALTH PROFILE BANGLADESH. MINISTRY OF HEALTH & FAMILY WELFARE (MOHFW)-BANGLADESH MOHFW is responsible to ensure basic health care to the people.
1 Health Care Reform in Hong Kong - Department of Health ’ s Perspective Dr Constance Chan Assistant Director of Health May 2001.
Pharmaceuticals Procurement and Supply Management: The case of Ethiopia Cambodia, December 4,
Presented to CSO workshops in Kabwe on 18 July 2014, Livingstone on 28 July 2014 and Lusaka on 27 August 2014.
Maternal, neonatal, child health and nutrition
Medicines Transparency Alliance (MeTA) Presented to CSO workshops during 2013 in SOLWEZI AUGUST 27 NDOLA AUGUST 29 LUSAKA OCTOBER 22.
Rational Use of Injections within National Drug Policies World health organisation Essential Drugs and Medicines Policy Safe Injection Global Network Cairo.
Does the Quality of Governance Contribute to the Quality of Health Care in Bangladesh? Presented by: Mohammad Shafiqul Islam Ph.D Candidate School of the.
USAID Update 2014 Bureau for Global Health Christine Malati, PharmD
Pharmaceutical Services Unit Essential Medicines Management
Pakistan.
Moving towards the goal of Universal Health Coverage (UHC) in Bangladesh Md. Ashadul Islam Director General Health Economics Unit Ministry of Health and.
EDM STRATEGY FOR WORKING WITH COUNTRIES-TANZANIA Rose Shija EDM NPO TANZANIA.
Essential Medicines Programmes Sudan now Essential Medicines Programmes Sudan now.
Aziza Parvin, Director, Bangladesh Bureau of Statistics (BBS) & Md. Eidtazul Islam, Senior Assistant Secretary, Statistics and Informatics Division (SID)
28 – 29 September 2011 Vedic Village Spa Resort Kolkata, India. Mohammad Dauod Khuram MD, MPH National Manager, Health Program Aga Khan Foundation, Afghanistan.
National Medicine Policy
MeTA Jordan Executive Summary Baseline data is an important source for policy makers to diagnose the pharmaceutical and health sector situation in order.
Health Indicators Mortality indicators Morbidity indicators
046:127 Pharmaceutical Management for Underserved Populations  Paper on Current Controversy  Team Assignment: Observational Visits  National Drug Policy/Assessment.
Towards Strengthening Procurement and Logistics Management System for the Ministry of Health and Bangladesh June 20, 2011.
Health System and Health System Strengthening in Nepal Dr BR Marasini, MBBS, MPH Senior Health Administrator Ministry of Health and Population.
Wilbert Bannenberg SARPAM
Public-Private Partnerships -Selected Experiences in the Western Pacific & Cambodia- National Forum on Public-Private Partnership in Health 7 November,
Cambodia1. 2 Cambodia Assessment Ung Phirun Chroeng Sokhan.
ASSESSMENT OF AVAILABILITY, PRICE AND AFFORDABILITY OF MEDICINES FOR CHILDREN IN GHANA Authors: Gyansa-Lutterodt M. 1,Andrews Annan E. 2, Koduah A. 1,
The Pharmaceutical Situational Analysis in Mongolia 1 Chimedtseren Munkhdelger 1 Sanjjav Tsetsegmaa 2, 1 Ministry of Health, 2 Pharmacy School, Health.
Tanzania1. 2 Tanzania Assessment Gabriel Upunda Tanzania3 DemographicsTanzania Area (sq km)945,100 Population 32,900,000 25% urban GNP per capitaUS $240.
ACCESS TO MEDICINES - POLICY AND ISSUES
MALAWI GOVERNMENT MINISTRY OF HEALTH PROGRESS ON GOOD GOVERNANCE IN THE PHARMACEUTICAL SECTOR IN MALAWI By Dr Charles Mwansambo Secretary for Health 20.
BASELINE SURVEYS AND MONITORING OF PHARMACEUTICAL SITUATION IN COUNTRIES. Joseph Serutoke NPO/EDM WHO Uganda November 2002.
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
MeTA Medicines Transparency Alliance: Under New Management Dr Tim Reed Director, Health Action International (Global) International MeTA Secretariat.
Yemaneberhan Taddesse.  PASDEP(plan of accelerated and sustainable development for the Eradication of poverty) Poverty reduction strategy is the main.
HEALTH FOR ALL BY YEAR 2000 AD (HFA) 1977 – WORD HEALHT ASSEMBLY - Attainment by all the people of the world by the year 2000 AD of a level of health that.
A BASELINE SURVEY OF THE PHARMACEUTICAL SECTOR IN TANZANIA
HEALTH A state of complete physical, mental and social well being and not merely the absence of disease or infirmity and ability to lead a socially and.
1 Pharmaceutical System Strengthening: Is There a Need for a New Paradigm? Douglas Keene, PharmD, MHS ICIUM-3 Pre-Conference Session 14 November 2011.
TBS 2008-H. Tata & M. Babaley Mapping and In-depth Assessment of Medicines Procurement and Supply Systems WHO Technical Briefing Seminar 17 th -21 st November.
Zambia Parliamentarian Presentation By Hon Munji Habeenzu Building North-South Partnership in Development: Strengthening Cooperation among Members of Parliaments,
GHANA HEALTH SERVICE, EASTERN REGION MID-YEAR REVIEW 2014 WAY FORWARD BY RDHS.
WHO Medicines Strategy Progress: Priorities: Dr Guitelle Baghdadi Essential Drugs and Medicines Policy World Health Organization November.
MONITORING THE PHARMACEUTICAL SECTOR IN A DEVELOPING COUNTRY - THE GHANA EXAMPLE Gyansa-Lutterodt M. 1,7, Andrews E 2, Arhinful D 3,7, Addo-Atuah J 4,7,
3rd WHO Prequalification Stakeholders Meeting :Diagnostics 3rd Stakeholders Meeting on Prequalification Geneva, 4th February 2008 Update on Prequalification.
CONSTRAINTS TO PRIMARY HEALTH CARE DELIVERY THE GOVERNMENT OBJECTIVES FOR DELIVERING PHC SERVICES To increase accessibility to quality health care services.
TANZANIA MAINLAND NATIONAL HEALTH POLICY AND STRATEGY REPORT.
ADDRESSING PHARMACEUTICAL SUPPLY CHAIN NEEDS PRESENTATION TO HEALTH DONOR GROUP MEETING 8 July 2009.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
MeTA Phase I: Where are we? MeTA18/06/ MeTA2 The MeTA Phase I Proposal Purpose To pilot a new multi-stakeholder approach towards increasing transparency.
Page Seite 1 Strengthening of the Private Sector Unit of MoH in development of partnerships with the private sector in health and social protection.
INTRODUCTION A national drug policy is a document which covers all the areas and issues related to drugs. This document outlines all aspects of drugs.
EDM Strategy for Working with Countries: the Uganda Example
University of Dhaka, Bangladesh
Malawi: Family Planning Program
Zambia’s Country Experiences
ACCESS TO QUALITY MEDICINES IN THE REGION-COUNTERFEITING PROBLEMS
EAST AFRICAN COMMUNITY MEDICINES REGULATORY HARMONIZATION (EAC-MRH) PROJECT PROGRESS NAIROB I - KENYA By: EAC - Secretariat.
WHO Medicines Work in Countries: The Kenya Example
Access to Medicines for HIV/AIDS, Tuberculosis and Malaria.
Richard Laing EMP/WHO TBS 2012
Bangladesh Population policy
Access to HIV/AIDS Medicines The 3x5 strategy
National Medicines Policies
Richard Laing WHO/PAU TBS 2013
Zambia’s Country Experiences
National Medicines Policies
An Enabling Business Environment and A Strategy and Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
Presentation transcript:

Pharmaceutical System Strengthening : Bangladesh Perspective Aktari Mamtaz Joint Secretary Ministry of Health and Family welfare (MOHFW), Bangladesh

2 Bangladesh: Country Profile  Country Area : sq. km.  Total Population : Million (BBS 2010)  Population Density (per sq. km.) : 993 persons (BBS 2009)  Life Expectancy at Birth- Male : 65.7 years (BBS 2009) Female : 68.3 years (BBS 2009)  Maternal Mortality Rate (MMR) ( per 1000 live births ) : 1.94 (BMMS 2010)  Infant Mortality Rate( per 1000 live births ) : 52 (BDHS 2007) (<1 Yr)  Neonatal Mortality Rate (<1 Month) : 37 percent (BDHS 2007)  Child Mortality Rate (<5 ) : 65 per 1000 live births (BDHS 2007) Per Capita Income :US$ 818

Achievements made so far Bangladesh has made considerable progress in high rates of economic growth and reducing poverty rates by 8 per cent between 2005 and In 2010, Bangladesh received the Millennium Development Goal (MDG) award for remarkable achievement in reducing child mortality (MDG 4). Bangladesh is also currently on track to meet MDG 5 (Maternal Health) Bangladesh received Digital Health for Digital Development award in 66 th UN General Assembly for contributing Maternal and Children Health through ICT.

Achievements made so far(cont.) Local pharmaceuticals contribute 90% of medicine production in Bangladesh. Leading 20 local companies have achieved recognition from International top regulatory authorities like,- UK, EU Australia, GCC(Gulf Cooperation Council), and many other regulatory authorities. Bangladesh pharmaceutical companies are now exporting medicines in 84 countries, among them UK, USA, Turkey, Thailand, Singapore etc. DGFP Supply Chain Information Portal (SCIP) has received two awards in e-Health and e-Governance category in the National Digital Innovation Award- 2011

Types of Pharmaceuticals in Bangladesh System No. of Producti on units Public DistributionNo. of Production units Private No. Of Pharmacy ( Distribution Outlets ) Allopathic1 Govt. health service centre Unani Ayurvedic Homeopathic79299 Herbal19Not known Source: Directorate General of Drug Administration, Bangladesh

Government’s Tools for Managing Pharmaceutical Sector & Improve Use of Medicines A dedicated department- Directorate Generals of Drug Administration National Drug Policy Since 1982, and updated in 2005 Drugs (Control) Ordinance,1982, reviewed in 2005 Drug rules and regulation, 1945 and 1946 Drug Testing Laboratory at Dhaka and at Chittagong

Government’s Tools for Managing Pharmaceutical Sector & Improve Use of Medicines(cont.) Essential drug lists for health professional (updated in 2008) to ensure rational use of medicines. Bangladesh National Formulary (last updated in 2006) for appropriate use of medicines. STGs (Standard Treatment Guidelines) for certain diseases – TB, leprosy, Malaria etc.

Management steps of pharmaceutical products in Bangladesh Registration: Any medicine either manufactured or imported should be registered to Directorate General of Drug Administration (DGDA) Selection: The Drug Control Committee of DGDA will select a medicine either for manufacture or import. Quality, safety, effficacy and usefulness is the criteria of selection. Production: After registration and Selection a manufacturer could go for production. An importer could import.

Management steps of pharmaceutical products in Bangladesh(cont.) Quality Assurance: According to NDP DGDA will ensure good quality medicines available at affordable price and WHO Good Manufacturing Practice (GMP) guidelines should followed by manufacturer’s. Procurement: According to requirement CMSD,DGHS and LMU,DGFP procure medicines and contraceptives for GOB service delivery centre's. Distribution: Govt. Chanel and Private Chanel. Web-based Logistics Management Information System (LMIS); Inventory Management Software for DGFP at Sub district and Warehouse level ensures good management of contraceptives distribution.

Stakeholders in Pharmaceutical Management in Bangladesh Pharmaceutical companies, Public / Private Health Service delivery facilities, Public/Private/ NGO Health Service Providers, Public/Private/NGO Importers Manufacturers Distributors Medicine Sellers Users/ patients

Medicine Supply Chain (Private): local production of drug: 83,850 million in 2010 Imported drug :10,710 million in 2010 Others Pharmacies (Retail drug shop) Manufacturers Importers

Source of medicines for patients seeking care *Source: HIES 2005 *92% of patients get their medicines from pharmacies or retail outlets.

Challenges/problems Lack of effective monitoring system Inadequate management capacity for effective implementation of existing legislation and policies and guidelines Quality assurance of the pharmaceuticals coupled due to lack of independent lab for testing products.

Challenges/problems Human Resources – inadequate trained staff. Lack of affordability – GOB’s resource constraint to pay for medicine procurement and also for Individuals to pay for medicines. Shortage of manpower in National Regulatory Authority.

Challenges/problems(cont.) Gaps and weaknesses in existing rules and regulations Inappropriate use of medicines – anybody can buy any medicine from medicine shops without prescription Lack of awareness & knowledge amongst users and availability of information

Way Forward… 1.Strengthen norms, standards and policy options; promote quality of medical products, vaccines and technologies. 2.Efficient procurement systems to combat counterfeit and sub- standard medical products, vaccines and technologies. 3.Promote good governance and transparency in procurement and medicines pricing.

Way Forward…(cont.) 4.Strengthening capacity of drug administration authority. 5.Ensure equitable access, rational use and adherence to quality medicine 6.Monitor quality and safety of products/vaccines/technologies. 7.Establish Active pharmaceutical Ingredients (API) park, which could enable local pharmaceutical companies to produce raw materials..

Way Forward…(cont.) Comprehensive capacity building plan for all relevant personnel involve in – supply chain management Effective expansion of Introduced telemedicine and e-health services Automated patient registration and medicines management system. Establish Procurement web portal under the Procurement and Logistics Management Cell (PLMC) of Ministry of Health and Family Welfare (MOHFW), which could help to track on line medicine procurement and supply.

Thank you